Baxter International Inc. has initiated a voluntary nationwide recall of a specific lot of its Cefazolin in Dextrose Injection, USP, 2G / 100ML, after cardboard particulate matter was discovered in the solution. The recall, announced on July 24, 2026, affects Lot LD175708 with an expiration date of February 14, 2027.
The presence of foreign particles in intravenously administered products carries significant health risks. According to Baxter, use of the defective product could reasonably lead to pulmonary emboli, occlusions of other blood vessels potentially causing tissue death and organ damage, and phlebitis.
Further potential complications include systemic activation of the immune system, organ dysfunction, and hemolysis, which is the breakdown of blood cells. Despite these serious risks, Baxter has confirmed that no adverse events related to this particular issue have been reported to date.